CTOs on the Move

HilleVax

www.hillevax.com

 
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.hillevax.com
  • 75 State Street Suite 100
    Boston, MA USA 02109
  • Phone: 617.213.5054

Executives

Name Title Contact Details
Anju Chatterji
Chief Technical Officer Profile

Similar Companies

SkinMedica

SkinMedica, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Excision BioTherapeutics

Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Virica Biotech

Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.

Ortho-McNeil Pharmaceutical

Ortho-McNeil Pharmaceutical, Inc. is a Raritan, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CervoMed

CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIPs development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.